Merz to expand and hunt for more deals after closing Inbrija buy
Jul 11, 2024 · After $185M asset buy, Merz Therapeutics plots US workforce expansion as CEO eyes more deals. Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz ...
Merz Enters Asset Purchase Agreement With a US-Based Biotech …
Apr 2, 2024 · FRANKFURT AM MAIN, Germany, April 02, 2024 -- (BUSINESS WIRE)-- Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial...
Merz Therapeutics Closes $185M Asset Purchase Agreement with …
Jul 10, 2024 · The completion of this deal, valued at USD 185 million in cash, bolsters Merz Therapeutics’ market position by enhancing offerings for people living with Parkinson’s disease and expanding into...
Merz Therapeutics Closes $185M Asset Purchase Agreement with …
Jul 10, 2024 · Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics. Acquisition of INBRIJA (levodopa inhalation powder) and (F)AMPYRA (fampridine) expands specialty neurology portfolio. Lays groundwork for Parkinson’s disease franchise and anchor in multiple sclerosis therapy.
News - Merz Pharma
Mar 1, 2023 · Merz enters Asset Purchase Agreement with a US-based biotech company. Second investment in a NASDAQ company in just over ten years. Frankfurt am Main, Germany / April 1, 2024 / Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered….
UPDATED: Acorda inks $185M asset sale to Merz, files for ...
Apr 9, 2024 · Germany’s Merz therapeutics, known for its Botox rival Xeomin, has stepped in to pick up the company’s Parkinson’s disease med Inbrija and multiple sclerosis drug Amprya (or Fampyra in Europe and...
Acorda Therapeutics Inc - Acorda Therapeutics and Merz …
Apr 1, 2024 · PEARL RIVER, N.Y.-- (BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.
Acorda Therapeutics and Merz Announce Signing of "Stalking …
Apr 1, 2024 · Acorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale. Acorda Enters into a Restructuring Support Agreement with over 90% of the Secured Convertible Noteholders. Patient ...
News & Press releases | Merz Therapeutics - North America (US)
Jul 30, 2024 · Merz Therapeutics Closes $185M Asset Purchase... Acquisition of INBRIJA (levodopa inhalation powder) and (F)AMPYRA (fampridine) expands specialty neurology portfolio. Lays groundwork for Parkinson’s disease franchise and anchor in multiple... Empowering Female Voices: A Conversation with...
News & Press releases | Merz Therapeutics
Oct 24, 2024 · Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, received approval from Swissmedic, the national authorization and supervisory authority for drugs and medical... Read More. News Release. 11.01.2024.